The Q1 results confirm the COVID-19 revenue decline trajectory is on track with guidance, but the widening net loss and CEO succession uncertainty create near-term overhang. The oncology pipeline catalysts (pumitamig Phase 2 data at ASCO, gotistobart Phase 3 interim, trastuzumab pamirtecan BLA filing) represent the primary value drivers for 2026. The $1.0B buyback provides a floor but does not offset fundamental deterioration. Monitor the May 29 ASCO data readout for pumitamig as a key inflection point.
Price Chart
Executive Summary
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY from €182.8M) and a net loss of €531.9M (vs. €415.8M loss a year ago), driven by declining COVID-19 vaccine sales. The company reaffirmed FY2026 revenue guidance of €2.0-2.3B and announced a planned $1.0B share repurchase program, a manufacturing consolidation affecting ~1,860 positions, and multiple oncology pipeline catalysts including six late-stage data readouts expected in 2026. The co-founders will transition to a new independent company by end of 2026, triggering a CEO/CFO succession search.
Key Facts
- Q1 2026 revenue of €118.1M, down 35.4% YoY from €182.8M
- Q1 2026 net loss of €531.9M, widening from €415.8M loss in Q1 2025
- Diluted loss per share of €2.10 (Q1 2025: €1.73)
- Cash, cash equivalents and security investments of €16.8B as of March 31, 2026
- FY2026 revenue guidance reaffirmed at €2.0-2.3B
- Planned share repurchase program of up to $1.0B over twelve months
- Manufacturing consolidation to exit sites in Idar-Oberstein, Marburg, Singapore and CureVac sites, affecting ~1,860 positions
- Expected recurring annual cost savings of ~€500M by 2029 from manufacturing consolidation
- Five additional pivotal trials for pumitamig initiated in Q1 2026 in collaboration with Bristol Myers Squibb
- Six late-stage pipeline data readouts expected in 2026 across immunomodulators, ADC and mRNA programs
- Co-founders Ugur Sahin and Ozlem Tureci to transition to new independent company by end of 2026; Supervisory Board initiated CEO/CFO succession search
- Gotistobart Phase 3 data showed 54% reduction in risk of death vs docetaxel in squamous NSCLC
- Trastuzumab pamirtecan BLA filing planned in 2026 for HER2-expressing endometrial cancer
Financial Impact
Revenue declined 35% YoY to €118.1M; net loss widened 28% to €531.9M; cash position remains strong at €16.8B; $1.0B buyback authorized; ~€500M annual cost savings targeted by 2029
Risk Factors
- Continued COVID-19 vaccine revenue decline faster than guided
- CEO/CFO transition creates strategic uncertainty and potential talent drain
- Oncology pipeline clinical trial failures or delays
- Manufacturing consolidation execution risk and associated exit costs
- Dilution from share repurchase program if not executed efficiently
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000030 |
| Document: a992bntx1q2026presentati.htm | 0001776985-26-000030 |
| Document: form6-kq12026earningsprear.htm | 0001776985-26-000030 |
| Document: 0001776985-26-000030-index-headers.html | 0001776985-26-000030 |
| Document: 0001776985-26-000030-index.html | 0001776985-26-000030 |
| Document: 0001776985-26-000030.txt | 0001776985-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.61 (−2.28%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.61 (+5.36%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.61 (−12.88%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.61 (+4.10%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.61 (−5.75%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.61 (+4.72%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.61 (+4.04%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.61 (+12.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access